Caplin Point Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The key equity indices pared their minor gains and traded near the flat line with a negative bias in the morning trade. The Nifty traded below the 22,550 mark. Financial services shares witnessed buying demand for the second consecutive trading session.

At 10:25 IST, the barometer index, the S&P BSE Sensex, declined 30.70 points or 0.04% to 74,.577.67. The Nifty 50 index shed 16.30 points or 0.07% to 22,531.25.

In the broader market, the S&P BSE Mid-Cap index declined 0.62% and the S&P BSE Small-Cap index fell 1.42%.

The market breadth was weak. On the BSE, 1,087 shares rose and 2,422 shares fell. A total of 178 shares were unchanged.

Buzzing Index:

The Nifty Financial Services index advanced 0.79% to 23,218.60. The index increased 0.97% for the second consecutive trading session.

Shriram Finance (up 3.79%), Cholamandalam Investment & Finance Company (up 3.67%), Bajaj Finserv (up 2.39%), Bajaj Finance (up 1.91%), Muthoot Finance (up 1.91%), SBI Cards & Payment Services (up 1.79%), ICICI Lombard General Insurance Company (up 1.5%), HDFC Bank (up 1.03%), ICICI Bank (up 0.61%) and Axis Bank (up 0.59%) advanced.

Stocks in Spotlight:

Caplin Point Laboratories shed 0.89%. The company’s subsidiary, Caplin Steriles, has received final nod from the United States Food and Drug Administration for its Abbreviated New Drug Application for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution.

Greenpanel Industries declined 3.04%. The company commissioned a new medium density fibreboard (MDF) plant at its existing unit in the Tirupati district (Andhra Pradesh), with an installed capacity of 2,31,000 cubic meters (CBM) per annum.

KP Green Engineering rose 0.53%. The company signed a memorandum of understanding (MoU) with the New and Renewable Energy Department of Madhya Pradesh (MP) for setting up of various solar, wind, hybrid, BESS, and biomass-based projects in Madhya Pradesh.

Powered by Capital Market - Live News

Caplin Steriles (Caplin), a subsidiary company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution (Eye drops), 0.2%/0.5% in 5mL, 10mL and 15mL fill presentation, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) COMBIGAN, by Abbvie Inc.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. According to IQVIA (IMS Health), Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution had US sales of approximately $242 million for the 12-month period ending December 2024.

Powered by Capital Market - Live News

The said drug is a generic therapeutic equivalent version of the Reference Listed Drug (RLD) COMBIGAN, by Abbvie Inc.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution are indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. According to IQVIA (IMS Health), the solution had US sales of approximately $242 million for the 12-month period ending December 2024.

Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets in Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms.

The company’s consolidated net profit grew 18.6% to Rs 138.96 crore on 13.2% increase in revenue from operations to Rs 492.96 crore in Q3 FY25 over Q3 FY24.

The counter shed 0.46% to settle at Rs 1,966.90 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.

Powered by Capital Market - Live News

Caplin Steriles (Caplin), a subsidiary company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution (Eye drops), 0.2%/0.5% in 5mL, 10mL and 15mL fill presentation, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) COMBIGAN, by Abbvie Inc.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. According to IQVIA (IMS Health), Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution had US sales of approximately $242 million for the 12-month period ending December 2024.

Powered by Capital Market - Live News

The said drug is a generic therapeutic equivalent version of the Reference Listed Drug (RLD) COMBIGAN, by Abbvie Inc.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution are indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. According to IQVIA (IMS Health), the solution had US sales of approximately $242 million for the 12-month period ending December 2024.

Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets in Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms.

The company’s consolidated net profit grew 18.6% to Rs 138.96 crore on 13.2% increase in revenue from operations to Rs 492.96 crore in Q3 FY25 over Q3 FY24.

The counter shed 0.46% to settle at Rs 1,966.90 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.

Powered by Capital Market - Live News

Net profit of Caplin Point Laboratories rose 18.57% to Rs 138.96 crore in the quarter ended December 2024 as against Rs 117.20 crore during the previous quarter ended December 2023. Sales rose 13.19% to Rs 492.96 crore in the quarter ended December 2024 as against Rs 435.50 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

The key equity indices pared their minor gains and traded near the flat line with a negative bias in the morning trade. The Nifty traded below the 22,550 mark. Financial services shares witnessed buying demand for the second consecutive trading session.

At 10:25 IST, the barometer index, the S&P BSE Sensex, declined 30.70 points or 0.04% to 74,.577.67. The Nifty 50 index shed 16.30 points or 0.07% to 22,531.25.

In the broader market, the S&P BSE Mid-Cap index declined 0.62% and the S&P BSE Small-Cap index fell 1.42%.

The market breadth was weak. On the BSE, 1,087 shares rose and 2,422 shares fell. A total of 178 shares were unchanged.

Buzzing Index:

The Nifty Financial Services index advanced 0.79% to 23,218.60. The index increased 0.97% for the second consecutive trading session.

Shriram Finance (up 3.79%), Cholamandalam Investment & Finance Company (up 3.67%), Bajaj Finserv (up 2.39%), Bajaj Finance (up 1.91%), Muthoot Finance (up 1.91%), SBI Cards & Payment Services (up 1.79%), ICICI Lombard General Insurance Company (up 1.5%), HDFC Bank (up 1.03%), ICICI Bank (up 0.61%) and Axis Bank (up 0.59%) advanced.

Stocks in Spotlight:

Caplin Point Laboratories shed 0.89%. The company’s subsidiary, Caplin Steriles, has received final nod from the United States Food and Drug Administration for its Abbreviated New Drug Application for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution.

Greenpanel Industries declined 3.04%. The company commissioned a new medium density fibreboard (MDF) plant at its existing unit in the Tirupati district (Andhra Pradesh), with an installed capacity of 2,31,000 cubic meters (CBM) per annum.

KP Green Engineering rose 0.53%. The company signed a memorandum of understanding (MoU) with the New and Renewable Energy Department of Madhya Pradesh (MP) for setting up of various solar, wind, hybrid, BESS, and biomass-based projects in Madhya Pradesh.

Powered by Capital Market - Live News

Caplin Steriles (Caplin), a subsidiary company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution (Eye drops), 0.2%/0.5% in 5mL, 10mL and 15mL fill presentation, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) COMBIGAN, by Abbvie Inc.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. According to IQVIA (IMS Health), Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution had US sales of approximately $242 million for the 12-month period ending December 2024.

Powered by Capital Market - Live News

The said drug is a generic therapeutic equivalent version of the Reference Listed Drug (RLD) COMBIGAN, by Abbvie Inc.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution are indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. According to IQVIA (IMS Health), the solution had US sales of approximately $242 million for the 12-month period ending December 2024.

Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets in Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms.

The company’s consolidated net profit grew 18.6% to Rs 138.96 crore on 13.2% increase in revenue from operations to Rs 492.96 crore in Q3 FY25 over Q3 FY24.

The counter shed 0.46% to settle at Rs 1,966.90 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.

Powered by Capital Market - Live News

Caplin Steriles (Caplin), a subsidiary company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution (Eye drops), 0.2%/0.5% in 5mL, 10mL and 15mL fill presentation, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) COMBIGAN, by Abbvie Inc.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. According to IQVIA (IMS Health), Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution had US sales of approximately $242 million for the 12-month period ending December 2024.

Powered by Capital Market - Live News

The said drug is a generic therapeutic equivalent version of the Reference Listed Drug (RLD) COMBIGAN, by Abbvie Inc.

Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution are indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. According to IQVIA (IMS Health), the solution had US sales of approximately $242 million for the 12-month period ending December 2024.

Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets in Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms.

The company’s consolidated net profit grew 18.6% to Rs 138.96 crore on 13.2% increase in revenue from operations to Rs 492.96 crore in Q3 FY25 over Q3 FY24.

The counter shed 0.46% to settle at Rs 1,966.90 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.

Powered by Capital Market - Live News

Net profit of Caplin Point Laboratories rose 18.57% to Rs 138.96 crore in the quarter ended December 2024 as against Rs 117.20 crore during the previous quarter ended December 2023. Sales rose 13.19% to Rs 492.96 crore in the quarter ended December 2024 as against Rs 435.50 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News